Overview

* Tango Therapeutics ( TNGX ) Q3 collaboration revenue increased significantly compared to the same period in 2024

* Company reports Q3 net income, reversing a net loss from the previous year

* $225 mln financing extends cash runway into 2028, supporting clinical trials

Outlook

* Company anticipates pivotal trial for vopimetostat in 2L MTAP-del pancreatic cancer in 2026

* Initial safety and efficacy data from vopimetostat + RAS(ON) inhibitors expected in 2026

* $225 mln financing extends Tango's cash runway into 2028

Result Drivers

* COLLABORATION REVENUE INCREASE - Significant increase in collaboration revenue due to recognition of deferred revenue from Gilead collaboration

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $53.81

Collabor mln

ation

Revenue

Q3 Net $15.88

Income mln

Q3 Basic $0.14

EPS

Q3 $39.73

Operatin mln

g

Expenses

Q3 $14.07

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Tango Therapeutics Inc ( TNGX ) is $12.50, about 35.9% above its November 3 closing price of $8.01

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)